EFFECT OF 50 mg ENTERIC‐COATED ASPIRIN (ASTRIX) ON THROMBOXANE AND PROSTACYCLIN SYNTHESIS

Publisher Website
Google Scholar
Abstract
Although low‐dose soluble aspirin can be recommended as a useful anti‐thrombotic drug regimen in patients with vascular disease, enteric‐coated preparations have a theoretical advantage for aspirin preparations which are to be ingested daily for many years. We have demonstrated that a 50 mg enteric‐coated aspirin formulation (astrix) which has an absorption rate much lower than soluble aspirin, is sufficient to inhibit platelet thromboxane synthesis while causing no major decrease in vascular prostacyclin synthesis.